臨床外科66巻7号

2011年07月発行

特集 術前薬物療法は乳癌手術を縮小させるか

術前化学療法と乳房温存術

著者： 髙田正泰¹ 戸井雅和¹

所属機関： ¹京都大学大学院医学研究科乳腺外科

ページ範囲：P.898 - P.902

【ポイント】

◆術前化学療法によって乳房温存率の上昇と切除範囲の縮小化が期待できる．

◆術前化学療法後の温存術の計画には画像検査による抗腫瘍効果のモニタリングが重要である．

◆バイオマーカーに基づく治療効果予測は切除範囲の適正化に役立つ可能性がある．

参考文献

1）Fisher B, Brown A, Mamounas E, et al：Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer：findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15：2483-2493, 1997

2）van der Hage JA, van de Velde CJ, Julien JP, et al：Preoperative chemotherapy in primary operable breast cancer：results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19：4224-4237, 2001

3）Bear HD, Anderson S, Brown A, et al：The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide：preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21：4165-4174, 2003

4）Smith IC, Heys SD, Hutcheon AW, et al：Neoadjuvant chemotherapy in breast cancer：significantly enhanced response with docetaxel. J Clin Oncol 20：1456-1466, 2002

5）Toi M, Nakamura S, Kuroi K, et al：Phase Ⅱ study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110：531-539, 2008

6）von Minckwitz G, Kummel S, Vogel P, et al：Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer：phase Ⅲ randomized GeparTrio trial. J Natl Cancer Inst 100：542-551, 2008

7）von Minckwitz G, Kummel S, Vogel P, et al：Intensified neoadjuvant chemotherapy in early-responding breast cancer：phase Ⅲ randomized GeparTrio study. J Natl Cancer Inst 100：552-562, 2008

8）von Minckwitz G, Raab G, Caputo A, et al：Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer：the GEPARDUO study of the German Breast Group. J Clin Oncol 23：2676-2685, 2005

9）Mieog JS, van der Hage JA, van de Velde CJ：Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007：CD005002

10）Mauri D, Pavlidis N, Ioannidis JP：Neoadjuvant versus adjuvant systemic treatment in breast cancer：a meta-analysis. J Natl Cancer Inst 97：188-194, 2005

11）Loo CE, Straver ME, Rodenhuis S, et al：Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy：relevance of breast cancer subtype. J Clin Oncol 29：660-666, 2011

12）Chen JH, Feig B, Agrawal G, et al：MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 112：17-26, 2008

13）Loo CE, Teertstra HJ, Rodenhuis S, et al：Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy：initial results. AJR Am J Roentgenol 191：1331-1338, 2008

14）Martincich L, Montemurro F, De Rosa G, et al：Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83：67-76, 2004

15）Lorenzon M, Zuiani C, Londero V, et al：Assessment of breast cancer response to neoadjuvant chemotherapy：is volumetric MRI a reliable tool? Eur J Radiol 71：82-88, 2009

16）Partridge SC, Gibbs JE, Lu Y, et al：MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184：1774-1781, 2005

17）Fangberget A, Nilsen LB, Hole KH, et al：Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2010 Dec3（Epub ahead of print）

18）Kumar A, Kumar R, Seenu V, et al：The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 19：1347-1357, 2009

19）Li XR, Cheng LQ, Liu M, et al：DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol 2011 Feb1（Epub ahead of print）

20）Tozaki M, Sakamoto M, Oyama Y, et al：Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31：895-902, 2010

21）Colleoni M, Bagnardi V, Rotmensz N, et al：Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116：359-369, 2009

22）Colleoni M, Viale G, Zahrieh D, et al：Expression of ER, PgR, HER 1, HER 2, and response：a study of preoperative chemotherapy. Ann Oncol 19：465-472, 2008

23）Guarneri V, Broglio K, Kau SW, et al：Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24：1037-1044, 2006

24）Darb-Esfahani S, Loibl S, Muller BM, et al：Identification of biology-based breast cancer types with distinct predictive and prognostic features：role of steroid hormone and HER 2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 11：R69, 2009

25）Parker JS, Mullins M, Cheang MC, et al：Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27：1160-1167, 2009

26）Rouzier R, Perou CM, Symmans WF, et al：Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11：5678-5685, 2005

27）von Minckwitz G, Untch M, Nuesch E, et al：Impact of treatment characteristics on response of different breast cancer phenotypes：pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125：145-156, 2011

28）Mazouni C, Kau SW, Frye D, et al：Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18：874-880, 2007

29）Daveau C, Savignoni A, Abrous-Anane S, et al：Is Radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys 79：1452-1459, 2010

30）Ring A, Webb A, Ashley S, et al：Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol 21：4540-4545, 2003

31）Denkert C, Loibl S, Noske A, et al：Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28：105-113, 2010

32）Ladoire S, Arnould L, Apetoh L, et al：Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3＋ regulatory T cells. Clin Cancer Res 14：2413-2420, 2008

33）Yerushalmi R, Woods R, Ravdin PM, et al：Ki67 in breast cancer：prognostic and predictive potential. Lancet Oncol 11：174-183, 2010